share_log

Cantor Fitzgerald Reiterates Overweight on Xenon Pharmaceuticals, Maintains $65 Price Target

Cantor Fitzgerald Reiterates Overweight on Xenon Pharmaceuticals, Maintains $65 Price Target

Cantor Fitzgerald再次对xenon制药股票持有超重评级,并维持65美元的价格目标。
Benzinga ·  2024/08/09 11:14  · 评级/大行评级

Cantor Fitzgerald analyst Josh Schimmer reiterates Xenon Pharmaceuticals (NASDAQ:XENE) with a Overweight and maintains $65 price target.

康泰菲茨杰分析师Josh Schimmer重申对xenon制药(纳斯达克:XENE)持超重评级并维持65美元目标价。

声明:本内容仅用作提供资讯及教育之目的,不构成对任何特定投资或投资策略的推荐或认可。 更多信息
    抢沙发